Nxera Pharma Co., Ltd.
Received a $3 Million Milestone from Centessa
Nexel Pharma received $3 million (approximately ¥473 million) from Centessa for achieving an early development milestone of the OX2R agonist ORX489 for neuropsychiatric disorders.
Key Figures
- Milestone Amount Received: $3 million (approximately ¥473 million)
- Revenue Recognition Period: FY2026 Q1
- Impact on Consolidated Earnings Guidance: Factored In
AI要約
Overview of Milestone Receipt
Nexel Pharma Inc. has received a new $3 million (approximately ¥473 million) milestone payment from its partner Centessa Pharmaceuticals Limited, following the achievement of an early development milestone for the orexin receptor 2 (OX2R) agonist ORX489 targeting neuropsychiatric disorders. This milestone will be recorded as revenue in the first quarter of the fiscal year ending December 2026.
Earnings Guidance and Future Outlook
The impact of this milestone on the consolidated earnings forecast for the fiscal year ending December 2026 has already been incorporated in the earnings guidance disclosed on February 13, 2026, with no revisions planned. Moving forward, the company will continue to advance numerous pipeline developments leveraging its proprietary drug discovery platform, NxWave™.
